Current evidence supports the view that BCR-ABL1 is the disease-causing mutation in chronic myelogenous leukemia (CML): (i) it is invariably present in CML and absent in other chronic myeloid malignancies; 1 (ii) it induces CML-like disease in mice; 2 and (iii) anti-BCR-ABL1 targeted therapy in CML results in complete and durable hematologic, cytogenetic and molecular remissions. 3 In an ongoing quest to identify BCR-ABL1-like mutations in other myeloproliferative neoplasms (MPNs), scientists have encountered an apparently endless number of mutations involving a spectrum of genes, including JAK2, MPL, LNK, CBL, IKZF1, IDH1, IDH2, TET2, ASXL1 and EZH2 (Table 1) . 4 In the current issue of Leukemia, three papers [5] [6] [7] report on yet another gene, DNMT3A, which is affected by somatic mutations in both BCR-ABL1-negative MPN and myelodysplastic syndromes (MDSs).
DNMT3A, DNMT3B and DNMT1 are DNA cytosine methyltransferases that are essential in establishing and maintaining DNA methylation patterns in mammals. 8, 9 Germline DNMT3B mutations have been associated with the autosomal recessive immunodeficiency, centromere instability and facial anomalies (ICF) syndrome. 10, 11 Heterozygous DNMT3AR882 mutations were first reported in acute myeloid leukemia (AML) by Yamashita et al. 12 in 3 (4%) of 74 patients. Subsequently, Ley et al. 13 described DNMT3AR882 (60% of mutant DNMT3A cases) and other heterozygous DNMT3A mutations in 62 (B22%) of 281 AML patients. In the latter study, DNMT3A mutations were enriched for older patients, normal karyotype and mutations involving FLT3, NPM1 and IDH1. Multivariable analysis identified mutant DNMT3A, older age and FLT3 mutations as risk factors for survival, but the particular observation was confounded by the inclusion of patients with favorable cytogenetic and molecular (NPM1-mutated/FLT3-unmutated) profiles; DNMT3A mutations were mutually exclusive of the former and did not affect survival in the latter group of patients. 13 In the current issue of Leukemia, Walter et al. 7 report on DNMT3A mutations in 12 (8%) of 144 patients with MDS (one patient had two DNMT3A mutations that made the total 13). As was the case with AML, R882, which is located in the methyltransferase domain, was the most frequent amino acid affected by these mutations (4 of 13 mutations; B31%). The other mutations were also located in the methyltransferase domain and included P904L (n ¼ 2), L737R, R771L, S770W, S714C, R635W, Q237X and L442X. DNMT3A mutational frequencies in MDS variants were 6% (4 of 67) for refractory anemia (RA), 8% (6 of 72) for RA with excess blasts (RAEB), 20% (1 of 5) for RA with ring sideroblasts (RARS), 10% (7 of 69) for MDS with normal karyotype, 6% (2 of 36) for MDS with complex karyotype and 6% (2 of 34) for MDS with either trisomy 8 or À7/del(7q). In this particular MDS study, sample size was too small and patient population too heterogeneous to properly assess the prognostic value of DNMT3A mutations, however, univariate analysis showed worse survival in DNMT3A-mutated cases. In another MDS study, Ewalt et al.
14 screened 100 patients with RAEB and found four cases (4%) with DNMT3AR882 mutations, one of which also harbored a second DNMT3A mutation (DNMT3AC709Y).
Also in the current issue of Leukemia, two papers report on DNMT3A mutations in patients with MPN. Stegelmann et al. 5 studied 46 patients with primary myelofibrosis, 22 with post-thrombocythemia/polycythemia vera MF and 11 with blast phase MPN; DNMT3A mutational frequencies were reported at 7, 0 and 0%, respectively. All 13 DNMT3A mutations reported in these two studies were heterozygous and included R882H/C (n ¼ 5), E477 (nonsense), E523 (nonsense), W305 (frameshift), R488 (frameshift), P264 (frameshift), D768 (frameshift), G120 (frameshift) and P419 (frameshift); additional DNMT3A sequence variants (unannotated single nucleotide polymorphisms vs missense mutations) that were reported included N501S, W860R, E30A, P99S, P569A, R659H and R899C. DNMT3A mutations in the aforementioned two MPN studies were documented to occur in the presence or absence of JAK2, IDH, ASXL1 or TET2 mutations.
The question now is whether or not we have been enlightened more about the pathogenesis of BCR-ABL1-negative MPN, as a result of a growing list of mutations they harbor. Are these mutations all critical drivers of the underlying myeloproliferative process or are some of the mutations simply markers of cancerassociated genomic instability? Which mutations are important for chronic phase disease and which ones contribute to disease transformation into myelofibrosis or AML? Is there more than one critical mutation for a specific disease phenotype? (i.e., Do multiple mutations share a common phenotype?) Alternatively, are we dealing with more than three diseases in the WHO category of BCR-ABL1-negative MPN? (i.e., Are we unintentionally lumping molecularly distinct diseases into a single clinicopathologic entity?)
It is becoming increasingly evident that currently known MPN-associated mutations likely represent secondary events, are not necessarily mutually exclusive and do not display a predictable pattern of clonal hierarchy. 15, 16 For example, in a recent report, a patient with normal karyotype primary myelofibrosis displayed four distinct mutations including JAK2V617F, IDH2R140Q and two LNK mutations affecting both parental LNK alleles; 17 single colony studies were carried out and disclosed one of the two LNK mutations as the first and JAK2V617F as the last event, in the order of clonal evolution. Others have shown that in patients with concomitant TET2 and JAK2 mutations, the two can involve separate clones or one can emerge before or after the other. 15 Furthermore, no one mutation has been directly implicated in leukemic Abbreviations: AML, acute myeloid leukemia; BP-MPN, blast phase MPN; aCML, atypical chronic myeloid leukemia, BCR-ABL1-negative; CMML, chronic myelomonocytic leukemia; CP-MPN, chronic phase MPN; ET, essential thrombocythemia; HES/CEL, hypereosinophilic syndrome/chronic eosinophilic leukemia; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; PMF, primary myelofibrosis; PV, polycythemia vera; RARS-T, refractory anemia with ring sideroblasts; SM, systemic mastocytosis. MF includes both PMF and post-ET/PV myelofibrosis.
Editorial transformation, which can involve either mutated or unmutated clones, in otherwise mutation-positive patients. 18 Among the currently known MPN mutations, JAK2, MPL and LNK mutations [19] [20] [21] [22] are the most noteworthy because: (i) they share similar functional consequences that include constitutive JAK-STAT activation and induction of MPN-like disease in mice; 19, 20, 22, 23 (ii) JAK2 mutations are by far the most prevalent and occur in virtually all patients with polycythemia vera 24 and in the majority of those with thrombocythemia or primary myelofibrosis; 25 and (iii) all three mutations are relatively specific to MPN. 26, 27 However, the fact remains that none of these three mutations can be traced back as the ancestral disease clone and small molecule drugs that target their common effector pathway have not produced clonal remissions. 28 Disease-specific pathogenetic relevance for non-JAK2 MPN mutations is further undermined by low mutational frequency and promiscuity within the spectrum of myeloid neoplasms (Table 1) (ref. 4) . The latter often involve genes that are thought to be epigenetically relevant, including TET2, ASXL1, IDH, EZH2 and now, DNMT3A.
29,30
Global DNA hypomethylation and regional hypermethylation of promoters for tumor suppressor genes are typical findings in cancer and are believed to contribute to genomic instability. 31 Such epigenetic changes might result from mutations that affect expression or function of DNA methyl transferases or other epigenetically relevant proteins such as TET2, which catalyzes conversion of 5-methylcytosine to 5-hydroxymethylcytosine 32 or EZH2, which is part of a histone methyl transferase complex. 33 Consistent with this view, there is evidence to suggest that DNMT3A 12,13 and MPN-associated EZH2 (ref. 34) mutations result in loss of function. Similarly, loss-of-function mutations involving TET2 might result in decreased generation of 5-hydroxymethylcytosine and, therefore, dysregulated regional hypermethylation. Furthermore, a recent paper suggested that mutant IDH might mimic the epigenetic effect of mutant TET2, by inhibiting the catalytic activity of wild-type TET2, through generation of 2-hydroxyglutarate. [35] [36] [37] Of note, JAK2 mutations might also have an epigenetic effect, the in vivo pathogenetic relevance of which is uncertain. 38, 39 Taken together, it seems that we need to re-examine our pathogenetic concept and treatment paradigm in BCR-ABL1-negative MPN. It is possible that we might never find BCR-ABL1-like mutations in these diseases, which undermines the prospect of an imatinib-CML-like experience. What we currently have is a laundry list of 'secondary' mutations, most of which can be operationally organized into JAK-STAT-relevant and epigenetically relevant mutations. The former (i.e., JAK2, MPL and LNK mutations) seem to be relatively specific to MPN and, in that context, are likely to represent driver mutations. The latter (i.e., TET2, EZH2, IDH, DNMT3A and possibly ASXL1) might carry a broader, albeit nonspecific, pathogenetic relevance that might include sustenance of the myeloid neoplasm stem cell and clonal evolution. At the same time, we should not be intimidated by the possibility that some mutations in either MPN or MDS might simply represent passenger mutations, regardless of what we think their functional relevance might be.
From a therapeutic standpoint, a better understanding of pathway wiring rather than description of new secondary mutations is more likely to lead to identification of a robust drug target. The big picture also requires consideration of the pathogenetic contribution of the interaction between host and tumor and the phenotype modifying and prognostic impact of abnormal cytokine expression. 40 Consistent with the latter view, cytokine modulation rather than direct cytotoxicity underlies the predominant mechanism of action for some of the currently available JAK inhibitors, which have recently been shown to have palliative value in myelofibrosis. 41, 42 JAK-STAT is not the only abnormal pathway in MPN and it might not even be the most important for clonal evolution. 18 Effective abrogation of clonal myeloproliferation and leukemic transformation in MPN might require therapeutic targeting of other pathways, in addition to or instead of JAK-STAT.
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